Skip to content

Evaluation of Bioresorbable Sheet to Prevent Intra-Abdominal Adhesions in Colorectal Surgeries

Evaluation of Intra-Abdominal Adhesions in Ileostomy Procedures When Using a Resorbable Polylactide Film (SurgiWrap) in Colorectal Surgeries

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00902148
Enrollment
19
Registered
2009-05-15
Start date
2003-12-31
Completion date
2007-03-31
Last updated
2009-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesions

Keywords

Surgery, Colectomy, Proctocolectomy, Adhesions

Brief summary

Study to investigate and determine the difference between the extent and severity of intra-abdominal adhesions in patients where SurgiWrap film was placed compared to patients with no adhesion barrier inserted. Hypothesis: Due to the preclinical safety data and clinical case reports in various indications it is anticipated that the surgical sites where the resorbable anti-adhesion barrier SurgiWrap was placed, there will be a reduction of adhesions compared to the control group with no treatment.

Interventions

SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.

Sponsors

MAST Biosurgery, AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 78 Years
Healthy volunteers
No

Inclusion criteria

* Patients with rectal cancer, ulcerative colitis or other pathologies requiring a second surgery for ileostomy closure. * Age between 18 and 78 years. * Patient or his/her legal representative has read and signed the approved Informed Consent form before randomization.

Exclusion criteria

* Previous abdominal operation through a midline approach * Use of hernia mesh * Use of any antiadhesive irrigants or irrigants containing corticosteroids, heparin, salicylates, nonsteroidal anti-inflammatory drugs. * Pregnancy

Design outcomes

Primary

MeasureTime frame
Assess the extent and severity of new formed adhesions having its source in the target region where the SurgiWrap film initially was placed: between the midline incision/scar and the omentum, and between the midline incision/scar and the small bowel6 to 8 months

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026